Amarin Corp Plc (AMRN)

[ziploc_1]

DMC8...."In Hikma’s press release Hikma refered to multiple uses of generic Vascepa....Amarin's lawyer emphasized that physicians observed Hikma’s press release and saw that its drug was the generic equivalent of Amarin’s drug. This, the lawyer argued, creates a question for the jury of inducement of infringement."

Why would Hikma NOT disclose on their generic meds' label that "this med is ONLY to be used for treatment of patients with triglycerides of over 500 mgs/dcl"?...The obvious answer is that Hikma would NEVER do this because...if they informed patients and Docs of that uncomfortable but legal fact, they would then lose 97% of the generic EPA's market share for the U.S.,which they now pull in by infringing on Amarin's CVD patents and which 97% of market share should, by law, be going to Vascepa.